Balaxi Pharmaceuticals Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Revenue growth shows a consistent upward trend, indicating strong market demand for pharmaceuticals.
Net profit margin has improved significantly, reflecting better cost management and operational efficiency.
Expansion into new markets has diversified revenue streams, reducing dependence on domestic sales.

NEGATIVES

Rising raw material costs have pressured profit margins, potentially impacting future profitability.
Increased competition in the pharmaceutical sector has led to pricing pressures, affecting market share.
Regulatory challenges in new markets could hinder growth prospects and delay product launches.

Field	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Jun 25
Revenue	65.95	54.72	60.79	59.83	65.62	77.38	73.29	70.74
Expenses	57.69	44.99	48.02	47.64	56.40	67.71	71.16	68.06
Operating Profit	8.26	9.74	12.76	12.19	9.22	9.67	2.13	2.68
Other Income	-1.01	0.28	-0.13	-1.79	-1.85	-4.11	3.94	-1.78
Interest	0.29	0.37	0.42	0.60	0.37	0.45	1.38	1.01
Depreciation	0.29	0.66	0.48	0.67	0.49	0.46	0.48	0.46
Profit Before Tax	-39.41	15.66	14.27	11.49	7.38	5.56	6.07	0.90
Tax	1.93	1.23	0.68	0.56	0.89	0.97	0.71	0.61
Net Profit	-41.34	14.43	13.59	10.93	6.48	4.59	5.36	0.29
Eps in Rs	-40.49	14.10	13.29	10.41	1.17	0.84	0.97	0.05